The future of inhaled insulin and incretinmimetics in the management of diabetes
- 31 December 2008
- journal article
- review article
- Published by Elsevier in Primary Care Diabetes
- Vol. 2 (1) , 59-61
- https://doi.org/10.1016/j.pcd.2008.01.001
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trialClinical Therapeutics, 2007
- Why is Exubera being withdrawn?BMJ, 2007
- ExenatideExpert Opinion on Pharmacotherapy, 2007
- Selection and education of patients for inhaled insulinCurrent Diabetes Reports, 2007
- Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 DiabetesAnnals of Internal Medicine, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a SulfonylureaDiabetes Care, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 DiabetesDiabetes Care, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004